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Abstract
Diabetes has evidence in ancient literatures, though recently is being considered as one amongst the most emerging 
disease condition in both human and companion animals. Diabetes mellitus is one of the common endocrinopathy of 
dog characterized by hyperglycemia, glycosuria and weight loss. Reports suggests high fraction of canine population 
suffer with diabetes world over. Studies in different veterinary hospitals of United States suggest increase in cases of 
canine diabetes and decrease in case fatality rate over time. Increase in cases of canine diabetes worldwide is attributed 
to awareness amongst pet owners, better veterinary health facilities, breed preferences by dog owners, increase 
dependence on commercial feeds, obesity, etc. Diabetes in most dogs is immune mediated and insulin dependent. 
Breed predisposition in canine is attributed to dog leukocyte antigen gene pool encoding form major histocompatibility 
complex-II molecules, however research is still underway. Diagnosis of diabetes still relies on blood sugar evaluation 
for screening of canine population, though many other diagnostic methods have shown promising benefits including 
measurement of fructosamine and glycated haemoglobin. Management of diabetes in dog is based on insulin therapy, 
diet modification and exercise. Use of oral anti-diabetics drugs in canine is limited though experimental studies have 
shown promising results. Alternative therapies have been explored, but only a few approaches have shown promise for 
clinical application.
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Introduction
Diabetes mellitus (DM) is one of the common 
metabolic disorders affecting middle-aged to geriatric 
dogs characterized by hyperglycemia, glycosuria and 
weight loss, resulting from absolute or relative defi-
ciency of insulin. Research on DM has caught atten-
tion of researchers globally. Most of these findings 
were experiments undertaken in dog and very few 
literatures are available as case reports and retrospec-
tive studies with respect to spontaneous DM in canine 
population. Above all, studies on diabetes in canine 
population of Asian countries are still under prelimi-
nary stages or not considered at all. However, sponta-
neous cases of canine DM has increased globally due 
to factors such as obesity, alteration in feeding habits, 
owner inattention, lack of awareness and advance-
ment in diagnosis. In the recent few years, DM in 
human population shows an emerging statistics and 
Asian population are at increased risk [1]. Research 
conducted on canine DM has direct implication on 
studying this disease in humans [2]. Thus, there is a 
need to review current status of DM in canine popula-
tion with respect to past efforts, present advancement, 
clinical presentations, diagnostic and manage mental 
practices.
Timeline Review
Diabetes was described as one of the first disease 
in Egyptian manuscript of antiquity characterized by 
condition similar to DM Type 1 as “too great empty-
ing of the urine” in early second century [3]. In and 
around fifth century Indian physicians also identified 
the disease and named it as madhumeha or “honey 
urine” signifying glycosuria as one of the important 
clinical presentation of DM. Aretaeusthe Cappadocian 
(30-90 A.D) named the disease diabetes from a Greek 
word diabainein which means “siphon” or “a passer 
through” to describe the polyuria and polydipsia 
(PU-PD) [4]. Avicenna (980-1027 A.D) was first to 
describe complications of diabetes including gan-
grene. The term “mellitus” meaning honey is a Latin 
word first used by Willis (1621-1675) as nomenclature 
for diabetes [5]. The hormone discovered by Banting 
and Best in 1921, was named insulin after successful 
treatment of diabetic patients using this hormone by 
Macleod after purification by Collip [6]. Diabetes in 
dogs was recognized at least 40 years prior to insulin 
discovery [7]. Von Mering and Minkowski in 1889 
first described the canine clinical signs of PU-PD to be 
associated with the presence of glucose in the pancre-
atectomized urine of dogs [8]. Alloxan synthesized in 
1818 was considered as representative drug for induc-
ing diabetes by necrosis of the endocrine beta cells in 
1940s followed by streptozocin in animal models [9]. 
The association between major histocompatibility 
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complex (MHC) genes and diabetes in human was 
first reported in 1970s by Nerup et al. [10]. Recently, 
an advanced single session of gene therapy has been 
demonstrated as a long-term cure for diabetes in 
a large animal model by the researchers from the 
Universitat Autonoma De Barcelona, led by Fatima 
Bosch in 2013.
Experimental Models for DM
Experimental studies for undertaking research 
on DM has relied on developing several animal 
models by inducing damage to the pancreas through 
either surgical or chemical and genetic manipulation. 
Animal models of DM are classified as spontaneous 
or secondary. The earliest animal model of DM was 
a pancreatomized dog in the 1880s, and many others 
pancreatomized laboratory animal models like rabbit 
have been used for diabetic studies [11]. Most exper-
iments on diabetes have been carried out in rodents, 
although studies have also been reported on the dog 
and other large animals. Use of animal models in dia-
betes research has been reviewed elaborately includ-
ing genetically modified animal models by several 
workers [12-16].
Streptozotocin (STZ) and alloxan (percent-
age ratio of 69:31) are by far the most frequently 
used drugs and this chemical model has been useful 
for the study of multiple aspects of the disease [14]. 
Both these drugs exert their diabetogenic action when 
administered either intravenously (i.v.), intra-peri-
toneally (i.p.) or subcutaneously (s.c.). Alloxan and 
STZ are toxic glucose analogues that preferentially 
accumulate in pancreatic beta (β) cells via the glucose 
transporter 2 [17]. The dose of these agents required 
for inducing diabetes depends on the animal species, 
route of administration and nutritional status. Alloxan 
(oxygenated pyrimidine derivative) was isolated by 
Brugnatelli in 1818 and named by Wöhler and Liebig 
in 1838 [9]. It was considered a representative drug 
for diabetes capable of inducing necrosis of the pan-
creatic  β cells in 1940s. The most frequently used 
i.v. dose of alloxan in rats is 65 mg/kg, but its effective 
dose must be higher when administered by i.p. or s.c. 
route [18]. I.p. administration of 150 mg/kg of alloxan 
monohydrate induced hyperglycaemia in about 75% 
of the treated rats [18]. STZ (glucosamine-nitrosourea 
compound) is a naturally occurring chemical that is 
particularly toxic to the insulin-producing β cells of 
the pancreas in mammals. STZ was first used as anti-
biotic and incidentally found to be toxic to pancreas, 
thus later used for inducing diabetes. STZ is the most 
commonly used chemical for experimental induction 
of diabetes in rodents. However, chronic experimen-
tation with STZ has reported side effects like devel-
opment of functioning insulinoma, high incidence 
tumours of kidney and liver [19] suggesting its onco-
genic action. The effect of 160 mg/kg of i.v. STZ 
injection was equivalent to that of 200 mg/kg of i.p. 
STZ injection in modulating blood glucose level [9].
Types of DM in Dog
DM in dog can be classified as either Type 1 
or Type 2. Most dogs suffer from Type 1 diabetes in 
which there is lack of insulin production and depen-
dency on external insulin for survival. In Type 2 
insulin, production is impaired along with an inade-
quate response to the hormone. Unlike human beings 
whether dogs have Type I or Type II, DM has rarely 
been determined, however most diabetic dogs (>50%) 
are thought to have a disease similar to Type I DM 
of humans and are insulin dependent [20]. Catchpole 
et al. [21] have classified canine DM into insulin 
deficiency diabetes (IDD) with absolute insulin defi-
ciency and insulin resistance diabetes (IRD) with 
relative insulin deficiency. IRD can complicate and 
progress to secondary IDD as an outcome of β cell 
loss in pancreas associated with uncontrolled hyper-
glycaemia. IDD is characterized by insulin defi-
ciency caused by auto-immune-mediated destruc-
tion of β cells. In IDD dogs there is no increase in 
insulin or C-peptide by stimulation of β cells of pan-
creas located in islets of Langerhans with glucose 
or glucagon, suggesting that β-cells are lost or has 
become unresponsive [22]. Immune mediated dam-
age to β cells by antibodies against β cells has been 
suggested in the pathogenesis of DM in dog [23]. In 
nearly half of the newly diagnosed cases of DM in 
dogs, antibody against β cells has been reported [24]. 
However, lymphocytic infiltration of islets is infre-
quently detected  in dogs. IRD in the canine popu-
lation is comparatively less and often results from 
insulin resistance and/or inadequate insulin produc-
tion or secretion by β cells [20].
The third form of DM though a type of IRD, has 
also been reported called as gestational DM (GDM), 
or diestrus-associated DM in dog [25]. The published 
reports suggest that GDM affects mainly middle-aged 
bitches in the latter half of gestation with a breed 
predisposition toward Nordic Spitz [25]. However, 
authors have a view that this predisposition may be 
related to either over-representation of the breed or 
vary depending on proportions of intact bitches in 
the base population or less number of samples stud-
ied. GDM has been reported to resolve within days 
to weeks after whelping or termination of pregnancy. 
GDM is attributed to reduced insulin sensitivity 
in healthy bitch after 1 month of gestation [26] and 
increase levels of progesterone [27]. Higher level of 
progesterone causes glucose intolerance and overt 
diabetes during diestrus in bitches, and it also stim-
ulates the mammary gland of bitches to produce 
growth hormone, which is a potent inducer of insu-
lin resistance [28]. Juvenile diabetes in canine, a form 
of IDD has also been reported and is particularly 
prevalent in golden retrievers, German shepherd and 
keeshonds [29]. Pre-diabetic form in the dog has been 
suggested in non-diabetic dogs with chronic pancre-
atitis due to β-cell loss [30].Available at www.veterinaryworld.org/Vol.7/November-2014/10.pdf
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Epizootiology
Available literature suggests that spontaneous 
canine DM has not been considered and investigated 
in canine population of Asian countries including 
India. There are limited studies on breed disposi-
tion, incidence, susceptibility, clinical characteristic 
and response to use of various interventions avail-
able for its management and control. Major works 
are focused on experimental rodent studies and hov-
ering mainly on evaluation of herbal plants and/or 
its extracts. However, the scenario is different with 
respect to research and findings on spontaneous as 
well as experimental induced DM in affluent coun-
tries. Recent trends indicate steep rise (32%) in 
cases of canine DM from 2006 to 2010 according to 
Banfield Hospital of USA [31]. One such study sug-
gests that diabetes currently develops in about 1 in 
500 dogs and 1 in 250 housecats [32,33]. Similarly, 
Guptill et al. [34] reported that prevalence of canine 
DM presented to veterinary teaching hospitals of 
Purdue University, USA increased from 0.19% in 
1970 to 0.64% in 1999. During the same time period 
the case-fatality rate decreased from 37% to 5% sig-
nifying increase in incidence and understanding of 
diabetes management in canine. Estimated prevalence 
of canine DM in United Kingdom is 0.32% [32]. 
A recent study carried out by researchers of Indian 
Veterinary Research Institute; Izatnagar indicate that 
canine DM strikes Indian dog population at quite high 
frequency [35]. Out of the total of 251 dogs of differ-
ent breeds screened for diabetes, 27 (10.88%) were 
found to be diabetic based on random blood sugar 
and relevant clinical parameters [35]. However, no 
clear understanding was reported with respect to risk 
groups and other factors related with spontaneous 
canine DM. Understanding on breed, age and sex as 
risk factors has been reported by many researchers 
globally. Breeds like Poodles, Keeshounds, Alaskan 
Malamutes, Finnish Spitzes, Miniature Schnauzers, 
Samoyed, Cairn Terrier, Bichon Frise and English 
Springer Spaniels are considered under high risk for 
spontaneous DM while German Shepherd, Cocker 
Spaniels, Collies and Boxers breeds are included in 
low risk group [21,34]. Breed susceptibility for DM 
and influences of genetic factors, specific genes and 
inheritance patterns are importunate areas under 
investigation by researchers globally. DM in most sus-
ceptible breeds of dogs has been associated with dog 
leukocyte antigen (DLA) gene encoding for major 
MHC Class II molecules located on canine chromo-
some 12, with similar haplotypes and genotypes [36]. 
MHC Class II are responsible for presenting antigen 
to T lymphocyte. Some DLA genes are monomor-
phic, and others loci are polymorphic in the canine 
population. Therefore depending on the variation in 
the gene pool of DLA, the susceptibility to autoim-
mune diseases varies and so the breed predisposition 
to canine DM [21]. Polymorphisms in the canine 
cytotoxic T-lymphocyte antigen four promoters and 
other immune response genes are associated with sus-
ceptibility to DM in many pedigree breeds. Gender 
susceptibility for canine DM seems inappropriate at 
young age of the canine population attributed to low 
incidence of disease. However, the male-female risk 
ratio has a predominance of females at older ages [29]. 
Similar predisposition was also reported in a study 
carried out in Bareilly by Indian Veterinary Research 
Institute, Izatnagar with 70.37% cases reported in 
female [35]. Aging has been considered as one of the 
important factor in canine DM. Canine DM mostly 
reported in middle age to old age dogs between 5 and 
12 years of age [37]. Metabolic disorder of lipids in 
old age dogs may lead to obesity and diabetes due to 
hyperlipidemia [38].
The etiology of DM in dogs seems multi-fac-
torial (Figure-1). Factors including obesity, diet, 
exposure to toxic chemicals/drugs that cause insulin 
resistance, immune-mediated destruction of islet cells 
[23], destruction of islet cells secondary to pancreati-
tis and other endocrinopathies are few amongst many 
influencing pathogenesis of canine DM. Extensive 
pancreatic damage, which likely results from chronic 
pancreatitis, is responsible for the development of 
diabetes in approximately 28% of diabetic dogs [39]. 
Hypertriglyceridemia has been proposed as a possible 
inciting cause of canine pancreatitis [40] and is com-
monly seen in diabetic dogs. All these factors can be 
further influenced by breed susceptibility explained 
above. The most common combinations of endocrine 
disorders of dogs are DM and hyperadrenocorticism, 
followed by hypoadrenocorticism and hypothyroid-
ism [41]. Diagnosis of canine DM has been found to 
be correlated with season with the incidence peaking 
in winter [42]. Environmental factors such as feed-
ing high-fat diets, lipemia and disturbances in lipid 
metabolism have been implicated as potential etiolog-
ical factors in dogs with obesity-associated pancreati-
tis [43], and have a role to play in disease progression. 
Figure-1:  Schematic diagram showing possible factors 
responsible for spontaneous diabetes mellitus, CLLA4: 
Cytotoxic T-lymphocyte antigen 4, DLA: Dog leucocyte 
antigen, VNTR: Variable number of tandem repeats.Available at www.veterinaryworld.org/Vol.7/November-2014/10.pdf
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Various other possible inflicting factors contributing to 
increase incidence of DM are urbanisation of human 
population and engagement in occupations ensuing 
change in lifestyle of pet dogs, more dependence on 
commercial pet food, lack of exercise, preference for 
breeds predisposed to DM [44].
Clinical Presentation of DM
The clinical presentation in most cases of canine 
DM are PU-PD, persistent hyperglycaemia, glycos-
uria and ketonuria [45]. On a perusal of available lit-
erature on spontaneous cases of DM in dog, very few 
references are available from Asia including India. 
Most case reports and studies available are restricted 
to USA, Australia and UK. Earliest and elaborative 
description of DM in dogs and cats was published by 
Hjärre [46]. Canine DM is an assorted disorder with 
several pathological mechanisms and complication 
of abnormal metabolism. Abnormal carbohydrate 
metabolism is responsible for the PU-PD and cataract 
formation in diabetic dogs. Altered fat metabolism is 
primarily responsible for hyperlipidemia, ketone pro-
duction and hepatic changes. Cataracts develop within 
5-6 months of diabetic dogs, and approximately 
80% will have significant cataract formation by 
16 months [47]. The onset of diabetic cataract involves 
several factors such as osmotic changes in the lens, 
glycosylation of structural proteins, and a decreased 
concentration of antioxidants [48]. Spontaneous 
lens capsule rupture associated with DM, cataract 
and rapid lens intumescence occurs in the dog [49]. 
Unlike human diabetes retinopathy, aqueous humor 
concentration of vascular endothelial growth factor in 
diabetic dogs are not higher than health dog and may 
have a protective function against development of 
diabetic retinopathy [50]. Observed clinical findings 
of untreated, undiagnosed diabetic dogs are lethargy, 
weight loss, increased hunger, poor coat and reduced 
immunity [51] possibly attributed to decreased tissue 
utilization of nutrients. Ketoacidosis and hyperglyce-
mic hyperosmolar non-ketotic syndrome are two seri-
ous and potentially life-threatening complications of 
DM. These forms of diabetes are often precipitated by 
concurrent diseases such as pyelonephritis, pancreati-
tis, pyometra, hyperadrenocorticism, renal and heart 
failure. Ketosis in diabetic dogs has been attributed to 
the glucagon-insulin ratio and most diabetic dogs with 
a serum ketone concentration >1000 μmol/L have a 
propensity to have lower serum insulin (<5 μU/mL) 
concentration [45]. Pregnancy in bitches results in 
suppressed intracellular transport of glucose causing 
hyperglycemia. Pregnant bitches also have suppressed 
ability to produce glucose in response to hypoglyce-
mic state and a slight deprivation of food may cause 
hypoglycemia and ketonemia [52].
Advances in Diagnosis of DM
Diabetic dogs are often undiagnosed in Asian 
countries including India attributed to lack of 
awareness amongst both pet owners and veterinary 
clinicians. This assumption is reflected based on 
the very few reports of canine DM from the region, 
though the actual number of cases in the canine pop-
ulation is underreported. Conventionally, diagnosis 
of canine DM is based on persistent hyperglycemia, 
and glucosuria accompanied with appropriate clinical 
signs. Blood glucose concentration for evaluation of 
DM is limited by the fact that it fluctuates with the 
time of the day, stress and often do not reflect the 
overall glycemic control of a dog. Normal reference 
values for blood glucose in health dog range from 75 
to 120 mg/dl [53]. The renal threshold for glucose 
is ~180 mg/dl [53]. Glycosuria is clinically present 
when blood sugar level exceeds this limit. In dogs 
diagnosis of immune-mediated DM can be evaluated 
by β-cell specific antibodies and C-peptide concentra-
tion. Measurement of C-peptide provides a sensitive, 
well accepted, and clinically validated assessment of 
β-cell function in human patients [54].
Measurements of serum fructosamine and gly-
cated hemoglobin (GHb) are increasingly used to 
complement blood glucose concentration to diag-
nose canine DM and to monitor the response to treat-
ment [55]. However, fructosamine has advantage over 
GHb based on simplicity and cost benefits of estima-
tion methods. Fructosamine can reflect glycemic con-
trol over the past 2-3 weeks while GHb can reflect the 
same for past 6-8 weeks. GHb is non-enzymatic and 
irreversible glycosylation of hemoglobin A1c. Haberer 
and Reusch [56] reported reference range of GHb for 
healthy and diabetic dog varying between 2.3-4.3% 
and 4.5-8.6%, respectively. The reported upper limit of 
serum fructosamine in dog is 374 μmol/L [57]. Serum 
fructosamine can also guide in differentiating primary 
renal glycosuria and Fanconi syndrome in dogs. In 
insulin treated diabetic dogs, concentrations of fasting 
blood sugar vary between 100 and 300 mg/dl, blood 
GHb ≤7.5%, and serum fructosamine ≤525 μmol/L 
[58]. Serum glycated albumin (GA) has been sug-
gested as an alternative to fructosamine and reported 
to be useful diagnostic indicator to monitor glycemic 
control in diabetic dogs [59]. In diabetic dog, serum 
GA concentrations reported as >11.9%. In diabetic 
dogs, high concentrations of aldose reductase are 
found in tissues of the crystalline lens, neurons and 
erythrocytes. The sorbitol concentration in erythro-
cytes was found significantly higher in diabetic dogs 
with ketonuria [48]. Serum canine pancreatic lipase 
immunoreactivity (cPLI) is considered as a sensitive 
marker for pancreatic inflammation in dogs [60]. 
Elevated serum cPLI concentration within the range 
diagnostic for pancreatitis has been reported in a small 
fraction of diabetic dogs [61,62].
Management Strategies for Canine DM
Most spontaneous cases of canine diabetes are 
insulin dependent. Uses of insulin and diet modifica-
tion are the two mainstays in management of diabetes Available at www.veterinaryworld.org/Vol.7/November-2014/10.pdf
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in canine. Most diabetic dogs suffer from insulin 
deficiency and require exogenous insulin. Insulin are 
injected s.c. Once daily, although administration twice 
daily can lead to better glycemic control and reduced 
risk of insulin-induced hypoglycemia. Commonly 
used insulin products in canine DM are isophane, 
lente and ultra-lente insulin. However, only two insu-
lin products for use in diabetic dogs are presently 
approved by Food and Drug Administration (FDA). 
One of these is a porcine lente product [63], the other 
is vetsulin (porcine insulin zinc suspension) approved 
by FDA in 2014. Vetsulin is the most preferred product 
used for management of canine DM, and its duration 
of action is about 12 h [64]. Protamine zinc insulin 
(PZI) is longer acting insulin but is currently approved 
for use in cats only. Use of recombinant human PZI 
has been demonstrated to significantly decrease mean 
10-h serum blood glucose and serum fructosamine 
concentration after 60 days of treatment [65]. The use 
of lantus insulin reported practical success both in 
dogs and cats [66]. Since lantus is long acting insulin, 
it has the advantage that it can be used once a day. 
Most dogs are well controlled on insulin at 0.5 U/kg 
repeated every 12 h with a range of 0.2 to 1.0 U/kg 
body weight [67]. Rucinsky et al. [64] recommend 
a starting dose of 0.25 U/kg every 12 h along with 
feeding equally sized meals twice daily at the time of 
insulin injection.
Most anti-diabetic drugs that are commercially 
available may not be useful in dog. Anti-diabetic 
drugs act either by stimulating insulin release by the 
β cells of the pancreas or by increasing the sensitivity 
of target organs to insulin or decreasing the rate of 
glucose absorption from the intestine. Commercials 
drugs used or available for the purpose are enlisted in 
Table-1. Baring a few anti-diabetic drugs, data with 
respect to dosing in dogs are not available. Treatment 
with the alpha glucosidase inhibitor (acarbose) 
improves glycaemic control in diabetic dogs [68]. 
In dogs, first-generation sulphonylureas exert a pos-
itive inotropic effect [69]. In fasted dogs, repaglinide 
have shown strong and long lasting hypoglycaemic 
effect [70]. The potency of repaglinide was reported 
to be higher and faster in action compared with glime-
piride and glibenclamide in the animal model [71].
Alternative therapies for canine DM have been 
studied, but only a few have reached its clinical appli-
cation. In surgical therapies, the first successful islet 
transplant was credited to Rundles and Swan [72]. 
Use of encapsulate islet in diabetes management, cur-
rent status and its future needs has been exhaustively 
reviewed [73]. Prochorov et al. [74] reported success-
ful intravascular xenotransplantation of macro-en-
capsulated pancreatic islet cells in Type 1 DM human 
patients. Micro-capsules using alginate or similar 
hydrogels encapsulate individual islets in rodents was 
found useful [75,76]. Reduction of encapsulated islet 
mass for clinical transplantation is in progress. Use of 
implant for clinical cases and its efficacy is still under 
process of understanding and development. Viral vec-
tor based gene therapy using adeno-associated virus 
encoding for glucokinase and insulin in canine dia-
betes had desirable effects consistently for consecu-
tive 4 years of study [77]. The same study has also 
been successfully undertaken in mouse’s model [78]. 
Nevertheless, further works are in the pipeline for 
the long-term cure of DM in dogs and humans which 
would harbinger innovative techniques to get rid of 
this royal disease.
Conclusions
Canine diabetes has emerged as an important 
endocrinopathy in middle to old age dogs globally. 
Diabetes was first described in Egyptian manu-
script of antiquity in early second century; how-
ever research and understanding of the disease is 
progressing. Canine DM can be broadly classified 
into IDD and IRD along with some other forms, the 
nomenclature of which can reasonably fit this classi-
fication. For inducing diabetes in the animal model, 
although many chemicals are available, the two 
most commonly used are streptozocin and alloxan. 
Insights on human diabetes are often based on exper-
imental studies carried out in the canine model. 
Clinical studies have shown that natural incidence of 
canine DM varies geographically. The predisposing 
factors precipitating the canine DM can be due to 
breeding preference, base population, lifestyle and 
occupational changes. Advancement in the research 
to understand the genetic basis of this disease is also 
under progression using various animal models. 
Table-1: Oral drugs available for use in DM.
Class Drug Dose Mechanism References
Biguanides Metformin 500-1700 mg/dog Decreases amount of glucose release 
from liver
Balogh et al., 2008; 
Mosallanejad et al., 2013
Sulfonylureas Glimepiride
Glipizide
2 mg SID
1 mg/kg
Stimulates the pancreas to release 
more insulin
Putnam et al., 1981
Alpha-glucosidase 
inhibitors
Acarbose 12.5-50 mg/dog
BID
Slows the absorption of carbohydrate Robertson et al. 1999
DPP-4 inhibitors Sitagliptin
Saxagliptin
Linagliptin
2-4 mg/day Slows the absorption of carbohydrate -
Meglitinides Repaglinide 0.5-1 mg/day More sensitive to the effects of insulin -
DM=Diabetes mellitus, DPP-4=Dipeptidyl-peptidase 4Available at www.veterinaryworld.org/Vol.7/November-2014/10.pdf
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Canine DM is an assorted disorder with several 
pathological mechanisms leading to hyperglycemia 
and complication of abnormal metabolism. Serum 
fructosamine and GHb are now increasingly used to 
complement blood glucose concentration for diag-
nosis of canine DM. Most diabetic dogs suffer from 
insulin deficiency and require exogenous insulin. 
Insulin used depends on the availability and licens-
ing of insulin for use in dog. However, research in 
this direction are still in infancy. Long acting insulin 
can facilitate dog owners in the management of DM. 
Experimental studies have shown potential for oral 
anti-diabetic drugs, however most have failed to find 
a place for clinical use in canine DM. Our progres-
sive efforts in the direction of alternative therapies 
such as gene implants, micro-devices, stem cells and 
viral based vectors have not yet reached significance 
for clinical use in canine DM.
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